^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Jivadco (trastuzumab duocarmazine) (HER2-targeted antibody-drug conjugate, DNA replication inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Published date:
06/27/2019
Excerpt:
Nine (28%, 95% CI 13·8-46·8) of 32 patients with HER2-low, hormone receptor-positive breast cancer and six (40%, 16·3-67·6) of 15 patients with HER2-low, hormone receptor-negative breast cancer achieved an objective response (all partial responses).
DOI:
10.1016/S1470-2045(19)30328-6
